Inventory

To date, the Company has obtained all of its Angiomax bulk drug substance from Lonza Braine, S.A. (Lonza Braine). On September 30, 2011, the Company entered into a supply agreement with Plantex USA Inc., an affiliate of Teva Pharmaceuticals USA, Inc., under which the Company will obtain Angiomax bulk drug substance. The Company also has separate agreements with Ben Venue Laboratories, Inc. and Patheon Italia S.p.A for the fill-finish of Angiomax drug product. As of September 30, 2011, the Company had inventory-related purchase commitments totaling $23.9 million during 2011, $57.2 million during 2012, $30.1 million during 2013, $7.5 million during 2014 and $7.5 million during 2015 for Angiomax and ready-to-use Argatroban bulk drug substance.

The major classes of inventory were as follows:



Inventory	September 30, 2011		December 31, 2010
	(in thousands)
Raw materials	$	8,079	$	9,801
Work-in-progress	16,217		7,183
Finished goods	6,130		8,359
Total	$	30,426	$	25,343

The Company reviews inventory, including inventory purchase commitments, for slow moving or obsolete amounts based on expected volume. If annual volume is less than expected, the Company may be required to make additional allowances for excess or obsolete inventory in the future.